Format

Send to

Choose Destination
Ophthalmology. 2016 Oct;123(10):2265-7. doi: 10.1016/j.ophtha.2016.06.027. Epub 2016 Jul 29.

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

Author information

1
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
2
Department of Ocular Oncology, Rotterdam Eye Hospital, Rotterdam, The Netherlands.
3
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
4
Department of Ocular Oncology, Rotterdam Eye Hospital, Rotterdam, The Netherlands; Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands.
5
Department of Ophthalmology, Radboud University Medical Centre, Nijmegen, The Netherlands.
6
Department of Ophthalmology, Erasmus Medical Centre, Rotterdam, The Netherlands.
7
Department of Ophthalmology, University Medical Center Groningen, Groningen, The Netherlands.
8
Department of Internal Medicine, Sint Franciscus Hospital, Rotterdam, The Netherlands.
9
Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
10
Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
11
Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands.
12
Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Medical Oncology, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom.
13
Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
14
Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands.
15
Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.
16
Department of Ophthalmology, Moorfields Eye Hospital and St. Bartholomew's Hospital, London, United Kingdom.
17
Department of Ocular Oncology, Rotterdam Eye Hospital, Rotterdam, The Netherlands; Department of Ophthalmology, Erasmus Medical Centre, Rotterdam, The Netherlands.
18
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: Jolanda.deVries@radboudumc.nl.
PMID:
27476772
DOI:
10.1016/j.ophtha.2016.06.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center